RxDoctor Payments Data

Thomas Kandora, MD

Internal Medicine · Hudson Falls, NYNPI 1144214503

Payments from drug & device makers

$2,492in general payments, 2019–2025

Across 135 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$433
  • GSK$363
  • AstraZeneca$249
  • Pfizer$181
  • Astellas Pharma US Inc$180
  • Lilly USA, LLC$126
  • plus $960 from 18 others

What the payments were for

  • Food & beverage$2,480100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,492 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$55,099
Medicare patients
199
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban296$233,636
JardianceEmpagliflozin211$213,460
TrulicityDulaglutide142$159,957
MounjaroTirzepatide79$91,078
OzempicSemaglutide64$79,698
Trelegy ElliptaFluticasone/Umeclidin/Vilanter101$64,977
FarxigaDapagliflozin Propanediol52$49,624
EntrestoSacubitril/Valsartan54$41,371
XareltoRivaroxaban39$25,058
JanuviaSitagliptin Phosphate29$23,833
Tresiba Flextouch U-200Insulin Degludec12$16,598
Breo ElliptaFluticasone/Vilanterol33$14,088
MyrbetriqMirabegron11$11,828
Atorvastatin Calcium722$8,622
Spiriva HandihalerTiotropium Bromide16$7,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$126$251,034221 claims
PfizerEliquis$181$233,636296 claims
Boehringer IngelheimJardiance, Stiolto Respimat$124$219,796224 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$363$84,091149 claims
Novo NordiskOzempic$433$79,69864 claims
AstraZenecaFarxiga, Symbicort$249$55,34276 claims
NovartisEntresto$42$41,37154 claims
MerckJanuvia$11$23,83329 claims
Astellas Pharma US IncMyrbetriq$180$11,82811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hudson Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →